



TML: CS: BSE/NSE CORR: 2022-23

03rd January, 2023

The Manager
Corporate Relationship Department
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051

Scrip Code – 530199

Symbol: THEMISMED

Sub: Press Release

Ref: 1. Regulation 30 of the SEBI (LODR) Regulations, 2015
2. BSE Scrip Code: 530199
3. NSE Scrip Code: THEMISMED

Dear Sir/Madam,

In terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a copy of the press release titled - **“Themis Medicare Launches Lenzetto® – Global brand of Estradiol Novel Drug Delivery System for treatment of Menopausal symptoms”**.

Kindly take this on record.

Thanking you,

Yours faithfully,

For Themis Medicare Ltd.

Sangameshwar Iyer
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India
***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621
Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat
CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219
***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com

PRESS NOTE CONTENT

Mumbai, India: 3rd January, 2023

“Themis Medicare Launches Lenzetto® – Global brand of Estradiol Novel Drug Delivery System for treatment of Menopausal symptoms”

As life span of women is increasing in India, post-menopausal health status assumes increasing importance in Women’s Healthcare. Most post-menopausal women remain unaware of the short and long-term implications of menopause due to lack of recognition of menopausal symptoms and unavailability of safe and convenient treatment options. **Themis Medicare Ltd. (Themis)**, a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the launch of a novel transdermal Estradiol spray **Lenzetto®** in the Indian market for treatment of Menopausal Symptoms.

Lenzetto® has a clinical experience in 40 countries and is approved by USFDA & EMA for the treatment of Menopausal Symptoms. **Lenzetto®** is manufactured in Europe by **Gedeon Richter, The Global Innovators in Women’s Health**.

Lenzetto® a novel transdermal estradiol with Metered Dose Transdermal Spray (MDTS Technology) delivers therapeutic doses of estradiol to the skin, using a metering pump containing 1.53 mg/spray estradiol hemihydrate. Transdermal delivery of estrogen is well established in clinical practice and ensures sufficient serum estradiol levels to alleviate Menopausal Symptoms like hot flashes, night sweats etc. at lower overall estradiol exposure while avoiding some of the consequences of high hepatic exposure and first-pass metabolism.

Clinical studies have shown that estradiol delivered in **Lenzetto®** 1.53 mg/spray transdermal spray formulation is absorbed through the skin and provides steady serum concentrations throughout 24 hrs. for the treatment of menopausal symptoms in peri-menopausal and postmenopausal women.

Various studies suggest that 1.53 mg estradiol transdermal spray is a valuable HRT option, demonstrating high acceptability and satisfaction amongst menopausal women, which enhances adherence to treatment. Guidelines from various Menopause Societies around the world like British Menopause Society, International Menopause Society and North American Menopause Society recommend Transdermal as a preferred route for Estradiol for treatment of Menopausal Symptoms.

Lenzetto® would be available on prescription.

Based on the product’s benefit, **Lenzetto®** *appears to offer another therapeutic option to Gynecologists for treating Menopausal symptoms in women with immense clinical benefit.*

Themis Medicare Limited

Corporate Office: 11/12, Udyog Nagar, S.V. Road, Goregaon (West), Mumbai- 400 104 India
Tel: 91 – 22 – 67607080 • Fax: 91 – 22 – 67607070 / 28746621
Regd. Office: Plot No.69-A, G.I.D.C. Industrial Estate, Vapi-396 195, Gujarat
CIN No: L24110GJ1969PLC001590 • Tel / Fax No: Regd. Off: 0260 2431447 / 2430219
• E-mail: themis@themismedicare.com • Website: www.themismedicare.com

Speaking at the release, *Dr. Sachin Patel, Managing Director & CEO* of Themis Medicare Ltd. said, “Our endeavor has always been to provide world class medicines that benefit patients and make healthcare far, far more effective. Given the fact that Gynecologists currently have limited treatment options for menopausal women, **Lenzetto® appears to offer a much needed therapeutic option to Gynecologists for treating Menopausal symptoms in women with immense clinical benefit and Convenience. Lenzetto® will provide Convenience to women as it is transdermal spray that Menopausal women can just “Spray and Go” unlike currently available transdermal Gel which are inconvenient and messy to apply. Lenzetto® will be promoted by a task force which will be exclusively meeting Gynecologists across the country.”**

According to Themis Medicare Limited, **Lenzetto®** is manufactured in and imported from **Gedeon Richter, Hungary. Lenzetto®** and will be available in a Transdermal Spray that facilitates “**Metered Dose Application**” **on to Small Skin Surface Area** in a unique easy to use packaging.

With a strong R&D backup, skilled domestic & export teams, and state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs and **Lenzetto®** launch is yet another step in this direction.

About Themis Medicare Ltd.

Themis Medicare was incorporated in 1969 as a joint venture partnership at Vapi. Today, it is one of the fastest growing pharma companies specializing in the development of complex molecules. With strong research focus on injectables, complex generic products and drug-delivery systems, the Company has evolved into being a formidable player in the complex generics space. It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The Company also has a significant export presence in the RoW geographies. The qualified and experienced Management team is complemented by highly skilled R&D workforce. The Company has three vertically integrated manufacturing facilities, of which two are focused on developing APIs – 1 each involved in manufacturing Synthetic API and Fermentation based API, and 1 is involved in manufacturing of Finished Dosage Formulations. Themis Medicare offers products in various dosage forms in multiple therapeutics areas with leadership in Pain Management and Critical Care. The Company has a strategy to focus and grow its injectable portfolio and develop its NDDS presence.

Themis Medicare Limited

Corporate Office: 11/12, Udyog Nagar, S.V. Road, Goregaon (West), Mumbai- 400 104 India
Tel: 91 – 22 – 67607080 • **Fax:** 91 – 22 – 67607070 / 28746621
Regd. Office: Plot No.69-A, G.I.D.C. Industrial Estate, Vapi-396 195, Gujarat
CIN No: L24110GJ1969PLC001590 • **Tel / Fax No:** **Regd. Off:** 0260 2431447 / 2430219
• **E-mail:** themis@themismedicare.com • **Website:** www.themismedicare.com